# Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

> **NCT04631744** · PHASE2 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 4 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT04631744
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-03
- **Primary completion:** 2025-05-12
- **Final completion:** 2025-11-09
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04631744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04631744, "Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04631744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*